Your browser doesn't support javascript.
Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
Raadsen, Matthijs P; Gharbharan, Arvind; Jordans, Carlijn C E; Mykytyn, Anna Z; Lamers, Mart M; van den Doel, Petra B; Endeman, Henrik; van den Akker, Johannes P C; GeurtsvanKessel, Corine H; Koopmans, Marion P G; Rokx, Casper; Goeijenbier, Marco; van Gorp, Eric C M; Rijnders, Bart J A; Haagmans, Bart L.
  • Raadsen MP; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
  • Gharbharan A; Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
  • Jordans CCE; Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
  • Mykytyn AZ; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
  • Lamers MM; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
  • van den Doel PB; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
  • Endeman H; Intensive Care Department, Erasmus MC, Rotterdam, The Netherlands.
  • van den Akker JPC; Intensive Care Department, Erasmus MC, Rotterdam, The Netherlands.
  • GeurtsvanKessel CH; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
  • Koopmans MPG; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
  • Rokx C; Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
  • Goeijenbier M; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
  • van Gorp ECM; Intensive Care Department, Erasmus MC, Rotterdam, The Netherlands.
  • Rijnders BJA; Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
  • Haagmans BL; Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
J Clin Immunol ; 42(2): 232-239, 2022 02.
Article in English | MEDLINE | ID: covidwho-1838372
ABSTRACT

PURPOSE:

To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during convalescent plasma treatment.

METHODS:

Sera from healthy controls, cases of COVID-19, and other respiratory illness were tested for IFN-α2 Abs by ELISA and a pseudo virus-based neutralization assay. The effects of disease severity, sex, and age on the risk of having neutralizing IFN-α2 Abs were determined. Longitudinal analyses were performed to determine association between IFN-α2 Abs and survival and viral load and whether serum IFN-α2 Abs appeared after convalescent plasma transfusion.

RESULTS:

IFN-α2 neutralizing sera were found only in COVID-19 patients, with proportions increasing with disease severity and age. In the acute stage of COVID-19, all sera from patients with ELISA-detected IFN-α2 Abs (13/164, 7.9%) neutralized levels of IFN-α2 exceeding physiological concentrations found in human plasma and this was associated with delayed viral clearance. Convalescent plasma donors that were anti-IFN-α2 ELISA positive (3/118, 2.5%) did not neutralize the same levels of IFN-α2. Neutralizing serum IFN-α2 Abs were associated with delayed viral clearance from the respiratory tract.

CONCLUSIONS:

IFN-α2 Abs were detected by ELISA and neutralization assay in COVID-19 patients, but not in ICU patients with other respiratory illnesses. The presence of neutralizing IFN-α2 Abs in critically ill COVID-19 is associated with delayed viral clearance. IFN-α2 Abs in COVID-19 convalescent plasma donors were not neutralizing in the conditions tested.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Plasma / Autoantibodies / Interferon alpha-2 / COVID-19 Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: J Clin Immunol Year: 2022 Document Type: Article Affiliation country: S10875-021-01168-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Plasma / Autoantibodies / Interferon alpha-2 / COVID-19 Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: J Clin Immunol Year: 2022 Document Type: Article Affiliation country: S10875-021-01168-3